LONDON (18 April 2023) – MMS Holdings, a data-focused contract research organization (CRO), has been named a Great Place to Work-Certified™ organization in the UK. This comes as the number of MMS colleagues based in the UK has doubled in just one year.
“We are proud to be certified as a Great Place to Work in the UK,” said Chris Schoonmaker, Chief Operating Officer, MMS. “Our growing number of UK colleagues exemplify our mission and core values, and their contributions to our global team has helped us be successful as an organization and advance life changing therapies to help patients and families worldwide. We plan to expand and grow in the UK and Europe to build on our teams and deliver value to our clients”
The certification is validated using employee feedback, and the accreditation confirms that at least 65% of employees have a consistently positive experience, but at MMS, the percentage was much higher. In addition, MMS scored highly for levels of camaraderie, positive leadership behavior, engagement, community, and respect.
“At MMS, we believe in creating a positive work environment for colleagues,” said Executive Director Alan Nicolle, who leads the UK team and has been with MMS since 2014. “By empowering our colleagues, we can provide the best solutions to our clients and positively contribute to the #OneMMS team across the globe.”
MMS prides itself on its exemplary culture, empowering its employees to enhance their work experiences, flexibility with work location and schedule, opportunities for advancement through the career ladder, and engaging global opportunities.
MMS was also recently named a Great Place to Work in India and a Top Workplace in the US.
“We congratulate MMS on achieving their Certification™,” said Benedict Gautrey, Managing Director of Great Place to Work® UK. “Organizations which put the employee experience at the heart of their business gain their employees’ trust and, in turn, are truly able to build a great workplace culture that delivers outstanding business results.”
About MMS
MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating.
Media Contact
Avery Zimmerman
media@mmsholdings.com
